PL1994410T3 - Sposoby wczesnego wykrywania raka - Google Patents

Sposoby wczesnego wykrywania raka

Info

Publication number
PL1994410T3
PL1994410T3 PL07706065T PL07706065T PL1994410T3 PL 1994410 T3 PL1994410 T3 PL 1994410T3 PL 07706065 T PL07706065 T PL 07706065T PL 07706065 T PL07706065 T PL 07706065T PL 1994410 T3 PL1994410 T3 PL 1994410T3
Authority
PL
Poland
Prior art keywords
methods
cancer
determining
kits
subject
Prior art date
Application number
PL07706065T
Other languages
English (en)
Inventor
Nadir Arber
Original Assignee
Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct filed Critical Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct
Publication of PL1994410T3 publication Critical patent/PL1994410T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL07706065T 2006-01-31 2007-01-31 Sposoby wczesnego wykrywania raka PL1994410T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76337806P 2006-01-31 2006-01-31
EP07706065A EP1994410B1 (en) 2006-01-31 2007-01-31 Methods for early detection of cancer
PCT/IL2007/000122 WO2007088537A2 (en) 2006-01-31 2007-01-31 Methods and kits for early detection of cancer or predisposition thereto

Publications (1)

Publication Number Publication Date
PL1994410T3 true PL1994410T3 (pl) 2011-12-30

Family

ID=38001788

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07706065T PL1994410T3 (pl) 2006-01-31 2007-01-31 Sposoby wczesnego wykrywania raka

Country Status (12)

Country Link
US (1) US9394569B2 (pl)
EP (1) EP1994410B1 (pl)
JP (1) JP5091163B2 (pl)
AT (1) ATE486285T1 (pl)
DE (1) DE602007010108D1 (pl)
DK (1) DK1994410T3 (pl)
ES (1) ES2355388T3 (pl)
IL (1) IL193097A (pl)
PL (1) PL1994410T3 (pl)
PT (1) PT1994410E (pl)
SI (1) SI1994410T1 (pl)
WO (1) WO2007088537A2 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007088537A2 (en) 2006-01-31 2007-08-09 Medical Research Fund Of Tel Aviv Sourasky Medical Center Methods and kits for early detection of cancer or predisposition thereto
US9034587B2 (en) 2007-12-10 2015-05-19 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Methods of diagnosing cancer
JP2012507300A (ja) * 2008-10-30 2012-03-29 カリス ライフ サイエンシズ ルクセンブルク ホールディングス Rnaパターンを評価する方法
EP2350320A4 (en) * 2008-11-12 2012-11-14 Caris Life Sciences Luxembourg Holdings METHOD AND SYSTEMS FOR USE OF EXOSOMES FOR THE DETERMINATION OF PHENOTYPES
EP2524059A4 (en) 2010-01-13 2013-11-20 Caris Life Sciences Luxembourg Holdings DETECTION OF GASTROINTESTINAL DISEASES
AU2011223789A1 (en) 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
JP5823505B2 (ja) 2010-05-21 2015-11-25 ザ・ガバナーズ・オブ・ザ・ユニバーシティー・オブ・アルバータ 尿中の代謝産物を測定することによる結腸直腸癌および結腸直腸ポリープの査定方法
EP3052651B1 (en) 2013-10-01 2019-11-27 Life Technologies Corporation Systems and methods for detecting structural variants
WO2018216006A1 (en) 2017-05-21 2018-11-29 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Combination of markers for diagnosing cancer
EP3447154A1 (en) * 2017-08-23 2019-02-27 Instytut Genetyki Sadowej Jolanta Powierska - Czarny Method for detection of mutations, polymorphisms and specific dna sequences on dna matrices with dna imaging techniques for the use in medical diagnostics and forensic genetics
US20200408761A1 (en) 2018-02-28 2020-12-31 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Methods of diagnosing and treating bladder cancer
KR20210111254A (ko) 2018-11-30 2021-09-10 캐리스 엠피아이, 아이엔씨. 차세대 분자 프로파일링
CN110777213A (zh) * 2019-11-05 2020-02-11 武汉科技大学 一种潜伏期胃癌诊断试剂盒
IL293489A (en) 2019-12-02 2022-08-01 Caris Mpi Inc predictor of pan-cancer platinum response
US11840720B2 (en) 2019-12-23 2023-12-12 Metabolomic Technologies Inc. Urinary metabolomic biomarkers for detecting colorectal cancer and polyps
MX2022009999A (es) 2020-02-14 2023-01-19 Caris Mpi Inc Puntuacion de prevalencia genomica panomica.
CN116397019A (zh) * 2022-10-27 2023-07-07 上海市同济医院 Cd24的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014157A1 (en) * 1991-02-05 1992-08-20 Kamal Bahar Simple test for detecting carcinoembryonic antigen
US5741650A (en) * 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
US7081516B2 (en) * 2002-08-26 2006-07-25 Case Western Reserve University Methods for categorizing patients
WO2003079982A2 (en) * 2002-03-19 2003-10-02 Tularik Inc. Gene amplification in cancer
US20040097448A1 (en) * 2002-11-19 2004-05-20 Isis Pharmaceuticals Inc. Modulation of CD24 expression
US20050130193A1 (en) * 2003-09-10 2005-06-16 Luxon Bruce A. Methods for detecting, diagnosing and treating human renal cell carcinoma
AU2004294547A1 (en) * 2003-11-26 2005-06-16 The Ohio State University Research Foundation Polymorphic CD24 genotypes that are predictive of multiple sclerosis risk and progression
CA2453198A1 (en) 2004-01-07 2005-07-07 Wei-Ping Min Quantification and generation of immune suppressive exosomes
EP1723428A2 (en) * 2004-02-19 2006-11-22 Yale University Corporation Identification of cancer protein biomarkers using proteomic techniques
WO2007088537A2 (en) 2006-01-31 2007-08-09 Medical Research Fund Of Tel Aviv Sourasky Medical Center Methods and kits for early detection of cancer or predisposition thereto

Also Published As

Publication number Publication date
US9394569B2 (en) 2016-07-19
JP5091163B2 (ja) 2012-12-05
ES2355388T3 (es) 2011-03-25
EP1994410B1 (en) 2010-10-27
SI1994410T1 (sl) 2011-03-31
DK1994410T3 (da) 2011-01-31
ATE486285T1 (de) 2010-11-15
PT1994410E (pt) 2011-01-10
WO2007088537A3 (en) 2007-10-25
EP1994410A2 (en) 2008-11-26
WO2007088537A2 (en) 2007-08-09
IL193097A0 (en) 2009-02-11
US20100062450A1 (en) 2010-03-11
IL193097A (en) 2013-03-24
JP2009525041A (ja) 2009-07-09
DE602007010108D1 (pl) 2010-12-09

Similar Documents

Publication Publication Date Title
SI1994410T1 (sl) Metode in kompleti za zgodnje odkrivanje raka ali predispozicije zanj
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2007089911A3 (en) Methods for detection of circulating tumor cells and methods of diagnosis of cancer in a mammalian subject
GB2463401B (en) Characterizing prostate disorders by analysis of microvesicles
BRPI0607508A2 (pt) métodos e ácidos nucléicos para análise de distúrbios proliferativos celulares
WO2013022995A3 (en) Biomarker compositions and methods
TW200643175A (en) Markers for prenatal diagnosis and monitoring
WO2009047756A3 (en) Methods and kits for diagnosing lung cancer
WO2006085984A3 (en) Immune cell biosensors and methods of using same
FI20050011A7 (fi) Menetelmä ja testipakkaus tyypin 2 diabetes mellituksen riskin havaitsemiseksi
WO2012174282A3 (en) Biomarker compositions and methods
WO2008117314A3 (en) Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2010004591A3 (en) Genetic variants for breast cancer risk assessment
WO2010033371A3 (en) Molecular markers for lung and colorectal carcinomas
WO2006076025A3 (en) Immune cell biosensors and methods of using same
WO2008140463A3 (en) Biomarker panels for assessing radiation injury and exposure
WO2007102891A3 (en) Materials and methods for assaying for methylation of cpg islands associated with genes in the evaluation of cancer
WO2006055524A3 (en) Biomarkers for diagnosing schizophrenia and bipolar disorder
WO2006002243A3 (en) Methods of oligosaccharide profiling for the detection of cancer
WO2007056523A3 (en) Methods for diagnosing and monitoring the progression of cancer
WO2006059252A3 (en) Methods and fluorinated compositions for treating amyloid-related diseases
WO2010020619A3 (en) Susceptibility to dasatinib
WO2008070325A3 (en) Genetic variations associated with tumors
EP1993672A4 (en) Na/k-atpase ligand
TW200643176A (en) ZNFN3A1/breast cancer related gene ZNFN3A1